Bruce J. Roth, MD

Specialty Areas
Medical Oncology
Prostate Cancer
Urologic Oncology

Additional Features and Interviews with Dr. Roth:

Ask the Expert - Seriousness of Blood in Urine for Males

Areas of Clinical Interest
Oncology, genitourinary oncology, solid tumor oncology, cancer, medical oncology, testicular cancer, germ cell tumors, kidney cancer, renal cell carcinoma, bladder cancer, and renal pelvis tumors.

Areas of Research Interest
Prostate cancer, urothelial cancer.

Honors and Awards
Listed in Best Doctors in America, 2011-2013 (Best Doctors, Inc.)

Recipient, ASCO Statesman Award, 2010

Recipient, 5-Star Patient Satisfaction Award, Vanderbilt University Medical Center, 2007, 2009

American Cancer Society Clinical Oncology Career Development Award, 1989-1992

Editorial Responsibilities

Editorial Boards
New Developments in Prostate Cancer Treatment
The Prostate Journal
Clinical Genitourinary Cancer
American Journal of Clinical Oncology
Journal of Clinical Oncology

Reviewer Responsibilities
Ad Hoc Journal Reviewer:
Annals of Internal Medicine
Blood
Cancer
Journal of Clinical Oncology
Cancer Investigation
Journal of Urology
Clinical Cancer Research
Cancer Chemotherapy and Pharmacology
Urologic Oncology
Oncology
British Journal of Cancer
Drugs
Cancer Research
Clinical Prostate Cancer

Selected or Recent Journal Articles
Kibel AS, Rosenbaum E, Kattan MW, Picus J, Dreicer R, Klein EA, Chatta GS, Nelson JB, DiPaola RS, Roth BJ, Cookson MS, Wilding G, Jarrard DF, Beer TM, Ryan CW, Petrylak DP, Benson MC, Partin AW, Garrett-Mayer E, Eisenberger MA. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol. 2007 May.

Dipaola RS, Chen Y-H, Stein M, Vaughn D, Patrick-Miller L, Carducci M, Roth B, White E, Wilding G. A Randomized Phase II Trial of Mitoxantrone, Estramustine and Navelbine or Bcl-2 Modulation with 13-cis Retinoic Acid, Interferon and Paclitaxel in Patients with Metastatic Hormone Refractory Prostate Cancer: ECOG 3899: Translational Medicine (in press)

Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin C-C, Rodon J, Murphy B, Roth B, McCaffery I, Gorski K, Kaiser B, Hwang Y, Zhu M, Deng H, Friberg G, Puzanov I. A Phase I Pharmacokinetic and Pharmacodynamic Study of AMG-479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor I. J Clin Oncol 27(34):5800-5807, 2009

Dreicer R, Li H, Stein M, DiPaola R, Eleff M, Roth BJ, Wilding G. Phase II Trial of Sorafenib (BAY43-9006) in Patients with Advanced Urothelial Cancer (E1804): A Trial of the Eastern Cooperative Oncology Group. Cancer 115(18): 4090-4095, 2009

Burgess EF, Ham A-JL, Tabb DL, Billheimer D, Roth BJ, Chang SS, Cookson MS, Hinton TJ, Cheek KL, Hill S, Pietenpol JA. Prostate Cancer Serum Biomarker Discovery Through Proteomic Analysis of Alpha-2 Macroglobulin Protein Complexes. Proteomics – Clinical Applications 2(9):1223-1233, 2008

Dreicer R, Li S, Li H, Cooney M, Wilding G, Roth BJ. Phase II Trial of Pemetrexed Disodium and Gemcitabine in Advanced Urothelial Cancer (E4802): A Trial of the Eastern Cooperative Oncology Group. Cancer 112(12):2671-2675, 2008

Dreicer R, Li S, Manola J, Haas N, Roth BJ, Wilding G. Phase II Trial of Epothilone B Analogue BMS-247550 in Advanced Carcinoma of the Urothelium (E3800): A Trial of the Eastern Cooperative Oncology Group. Cancer 110(4):759-763, 2007

Ryan CJ, Stadler WM, Roth B, Hutcheon D, Conry S, Puchalski T, Morris C, Small EJ. Phase I Dose Escalation and Pharmacokinetic Study of AZD2171, a Highly Potent VEGFR Tyrosine Kinase Inhibitor, in Patients with Hormone Refractory Prostate Cancer. Invest New Drug 25(5):445-451, 2007

Kibel A, Rosenbaum E, Kattan MW, Picus J, Dreicer R, Klein E, Chatta GS, Nelson JB, Dipaola RS, Roth BJ, Cookson MS, Wilding G, Jarrad DF, Beer TM, Ryan CW, Petrylak D, Benson MC, Partin AW, Garrett-Mayer E, Eisenberger M. Adjuvant Weekly Docetaxel for High-Risk Prostate Cancer Patients after Radical Prostatectomy: a Multi-Institutional Pilot Study. J Urol 177(5):1777-1781, 2007

Dreicer R, Petrylak D, Agus D, Roth B. Phase I/II Study of Bortezomib Plus Docetaxel in Patients with Advanced Androgen-Independent Prostate Cancer. Clinical Cancer Research 13(4):1208-1215, 2007

Girasole CR, Cookson MS, Smith JA, Ivey BS, Roth BJ, Chang SS. Sperm Banking: Use and Outcomes in Patients Treated for Testicular Cancer. Br J Urol 99(1):33-36, 2007

Sonpavde G, Hutson TE, Roth BJ. Management of Recurrent Testicular Germ Cell Tumors. The Oncologist, 12:51-61, 2007

For more articles and abstracts, take this off-site link to the National Library of Medicine Pub Med page for Dr. Roth

Internal Medicine / Oncology

---

Internal Medicine / Oncology - Medical Oncology

---

Cancer Center (Siteman Cancer Center)

---

Health Insurance Plans Accepted

Back to Physician's Directory